DFO
BMRN icon

Duquesne Family Office’s BioMarin Pharmaceuticals BMRN Stock Holding History

Duquesne Family Office’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-192,700
Closed -$16.9M – 65
2020
Q4 		$16.9M Hold
192,700
– – 0.46% 40
2020
Q3 		$14.7M Hold
192,700
– – 0.43% 42
2020
Q2 		$23.8M Buy
+192,700
New +$19.2M 0.73% 33

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Duquesne Family Office's BMRN Position: Q1 2021 in Review

Duquesne Family Office sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2021, closing a stake of 192,700 shares — an estimated $16.9M sold.

Duquesne Family Office first reported a position in BMRN in Q2 2020 and held it in 3 quarters. The position peaked at $23.8M in Q2 2020. 530 funds tracked by Wall St. Rank hold BMRN as of Q1 2021.

  • Duquesne Family Office reported no remaining BioMarin Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Duquesne Family Office sold 192,700 BioMarin Pharmaceuticals shares in Q1 2021, an estimated $16.9M.
  • Duquesne Family Office first reported a position in BioMarin Pharmaceuticals in Q2 2020 and held it in 3 quarters.
  • Duquesne Family Office's BioMarin Pharmaceuticals position peaked at $23.8M in Q2 2020.
  • 530 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2021.

Based on Duquesne Family Office's 13F filing for Q1 2021, filed 17 May 2021.